Mechanics Bank Trust Department trimmed its holdings in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 7.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 64,844 shares of the biopharmaceutical company’s stock after selling 4,887 shares during the period. Mechanics Bank Trust Department’s holdings in Bristol-Myers Squibb were worth $2,693,000 at the end of the most recent quarter.
A number of other large investors have also added to or reduced their stakes in the business. Northwest Financial Advisors bought a new position in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $27,000. ESL Trust Services LLC acquired a new stake in shares of Bristol-Myers Squibb during the first quarter worth $27,000. Accordant Advisory Group Inc acquired a new stake in shares of Bristol-Myers Squibb during the first quarter worth $31,000. Pacific Capital Wealth Advisors Inc. bought a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at about $34,000. Finally, Turtle Creek Wealth Advisors LLC acquired a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at about $40,000. Institutional investors own 76.41% of the company’s stock.
Bristol-Myers Squibb Trading Down 0.3 %
Shares of BMY stock traded down $0.13 during trading hours on Friday, hitting $46.72. 14,083,504 shares of the company’s stock traded hands, compared to its average volume of 15,967,806. The company has a quick ratio of 0.99, a current ratio of 1.16 and a debt-to-equity ratio of 2.86. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.41. The stock has a market cap of $94.71 billion, a PE ratio of -15.07, a price-to-earnings-growth ratio of 12.51 and a beta of 0.44. The stock’s 50 day simple moving average is $43.02 and its 200 day simple moving average is $46.60.
Bristol-Myers Squibb Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Thursday, August 1st. Stockholders of record on Friday, July 5th were given a $0.60 dividend. The ex-dividend date of this dividend was Friday, July 5th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.14%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -77.42%.
Analysts Set New Price Targets
BMY has been the topic of a number of analyst reports. BMO Capital Markets decreased their target price on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday, April 26th. Barclays cut Bristol-Myers Squibb from an “overweight” rating to an “equal weight” rating and set a $41.00 price objective for the company. in a report on Monday, July 29th. Wells Fargo & Company raised their price target on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 18th. Deutsche Bank Aktiengesellschaft dropped their price target on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a research note on Tuesday, July 23rd. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $45.00 price objective on shares of Bristol-Myers Squibb in a research note on Monday, July 22nd. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $55.79.
Check Out Our Latest Analysis on BMY
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Featured Articles
- Five stocks we like better than Bristol-Myers Squibb
- How to Choose Top Rated Stocks
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- When to Sell a Stock for Profit or Loss
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- The Significance of Brokerage Rankings in Stock Selection
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.